JP2002540189A - ジアリール誘導体およびその医薬としての使用 - Google Patents

ジアリール誘導体およびその医薬としての使用

Info

Publication number
JP2002540189A
JP2002540189A JP2000607982A JP2000607982A JP2002540189A JP 2002540189 A JP2002540189 A JP 2002540189A JP 2000607982 A JP2000607982 A JP 2000607982A JP 2000607982 A JP2000607982 A JP 2000607982A JP 2002540189 A JP2002540189 A JP 2002540189A
Authority
JP
Japan
Prior art keywords
dimethylphenyl
hydroxy
acid
hydroxyphenoxy
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000607982A
Other languages
English (en)
Japanese (ja)
Inventor
パイビ・ヤーナ・クッコラ
Original Assignee
ノバルティス アクチエンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アクチエンゲゼルシャフト filed Critical ノバルティス アクチエンゲゼルシャフト
Publication of JP2002540189A publication Critical patent/JP2002540189A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C317/22—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/64—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton
    • C07C323/67—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton containing sulfur atoms of sulfonamide groups, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
JP2000607982A 1999-03-29 2000-03-27 ジアリール誘導体およびその医薬としての使用 Pending JP2002540189A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28010599A 1999-03-29 1999-03-29
US09/280,105 1999-03-29
PCT/EP2000/002683 WO2000058279A1 (en) 1999-03-29 2000-03-27 Diaryl derivatives and their use as medicaments

Publications (1)

Publication Number Publication Date
JP2002540189A true JP2002540189A (ja) 2002-11-26

Family

ID=23071698

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000607982A Pending JP2002540189A (ja) 1999-03-29 2000-03-27 ジアリール誘導体およびその医薬としての使用

Country Status (21)

Country Link
EP (1) EP1165502A1 (xx)
JP (1) JP2002540189A (xx)
KR (1) KR20010105394A (xx)
CN (1) CN1345309A (xx)
AU (1) AU4290800A (xx)
BR (1) BR0009431A (xx)
CA (1) CA2361016A1 (xx)
CO (1) CO5160290A1 (xx)
CZ (1) CZ20013449A3 (xx)
HK (1) HK1042692A1 (xx)
HU (1) HUP0200588A2 (xx)
IL (1) IL144637A0 (xx)
MX (1) MXPA01009843A (xx)
NO (1) NO20014702L (xx)
NZ (1) NZ514062A (xx)
PE (1) PE20001587A1 (xx)
PL (1) PL349355A1 (xx)
RU (1) RU2001126579A (xx)
SK (1) SK13812001A3 (xx)
TR (1) TR200102225T2 (xx)
WO (1) WO2000058279A1 (xx)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007512359A (ja) * 2003-11-19 2007-05-17 メタバシス・セラピューティクス・インコーポレイテッド 新規なリン含有甲状腺ホルモン様物質
JP2017522329A (ja) * 2014-08-14 2017-08-10 嘉▲興▼特科▲羅▼生物科技有限公司Ｔｅｃｈｎｏｄｅｒｍａ Ｍｅｄｉｃｉｎｅｓ Ｐｔｅ Ｌｔｄ 小分子化合物、その合成方法、及びその応用

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2363145C (en) 1999-03-01 2006-02-14 Pfizer Products Inc. Oxamic acids and derivatives as thyroid receptor ligands
US6790978B2 (en) 1999-03-29 2004-09-14 Novartis Ag Thyromimetic organic compounds
MXPA02007929A (es) 2000-02-17 2003-02-10 Squibb Bristol Myers Co Ligandos derivados de anilina para el receptor de la tiroides.
IL151376A0 (en) * 2000-03-31 2003-04-10 Pfizer Prod Inc Malonamic acids and derivatives thereof as thyroid receptor ligands
US6664291B2 (en) 2000-03-31 2003-12-16 Pfizer, Inc. Malonamic acids and derivatives thereof as thyroid receptor ligands
WO2001085670A1 (fr) * 2000-05-12 2001-11-15 Kissei Pharmaceutical Co., Ltd. Derives d'acide malonanilique, compositions medicinales les contenant et leur utilisation
US6395784B1 (en) 2000-06-07 2002-05-28 Bristol-Myers Squibb Company Benzamide ligands for the thyroid receptor
DE10038007A1 (de) 2000-08-04 2002-02-14 Bayer Ag Neue Amino-und Amido-Diphenylether für Arzneimittel
DE10046029A1 (de) 2000-09-18 2002-03-28 Bayer Ag Indazole
AU2002223626A1 (en) * 2000-10-20 2002-04-29 Novartis Ag Combinations of a thyromimetic compound and a statin
CA2433100A1 (en) 2000-12-27 2002-07-04 Helmut Haning Indole derivatives as ligands of thyroid receptors
US6777442B2 (en) 2001-03-12 2004-08-17 Bayer Aktiengesellschaft Diphenyl derivatives
DE10122443A1 (de) * 2001-05-09 2002-11-14 Bayer Ag Amido-Diphenyl-Derivate
US6777443B2 (en) 2001-05-15 2004-08-17 Novartis Ag Dipeptide derivatives
ES2267945T3 (es) * 2001-05-31 2007-03-16 Pfizer Products Inc. Uso medico de compuestos tiromimeticos para tratar la perdida del cabello y composiciones.
DE10131462A1 (de) * 2001-06-29 2003-01-09 Bayer Ag Phenol-Derivate
EP1297833B1 (en) 2001-09-26 2005-12-21 Pfizer Products Inc. Indole carboxylic acids as thyroid receptor ligands
US6818766B2 (en) 2002-10-02 2004-11-16 Synthon Bv Process for making bicalutamide and intermediates thereof
WO2005105712A1 (en) * 2004-05-05 2005-11-10 Novo Nordisk A/S Sulfonamide derivatives
RU2416608C2 (ru) 2004-08-06 2011-04-20 Оцука Фармасьютикал Ко., Лтд. Ароматическое соединение
MX2007014502A (es) 2005-05-26 2008-02-07 Metabasis Therapeutics Inc Tiromimeticos para el tratamiento de enfermedades del higado graso.
MY146514A (en) 2005-12-05 2012-08-15 Otsuka Pharma Co Ltd Diarylether derivatives as antitumor agents
UA95978C2 (xx) 2006-10-02 2011-09-26 Оцука Фармас'Ютікел Ко., Лтд. Інгібітор активації stat3/5$ингибитор активации stat3/5
WO2009133834A1 (ja) * 2008-04-28 2009-11-05 塩野義製薬株式会社 血管内皮リパーゼ阻害活性を有するケトアミド誘導体
TW201512171A (zh) 2013-04-19 2015-04-01 Pfizer Ltd 化學化合物
EP3541395A4 (en) 2016-11-21 2020-07-01 Viking Therapeutics, Inc. GLYCOGENOSIS TREATMENT METHODS
US11707472B2 (en) 2017-06-05 2023-07-25 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis
CN112135832A (zh) 2018-03-22 2020-12-25 维京治疗公司 化合物的晶型和制备化合物的晶型的方法
TW202115029A (zh) * 2019-07-31 2021-04-16 大陸商深圳微芯生物科技股份有限公司 雜環化合物及其用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE159515T1 (de) * 1992-07-21 1997-11-15 Ciba Geigy Ag Oxamidsäure-derivate als hypocholesterämische mittel

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007512359A (ja) * 2003-11-19 2007-05-17 メタバシス・セラピューティクス・インコーポレイテッド 新規なリン含有甲状腺ホルモン様物質
JP2017522329A (ja) * 2014-08-14 2017-08-10 嘉▲興▼特科▲羅▼生物科技有限公司Ｔｅｃｈｎｏｄｅｒｍａ Ｍｅｄｉｃｉｎｅｓ Ｐｔｅ Ｌｔｄ 小分子化合物、その合成方法、及びその応用

Also Published As

Publication number Publication date
CA2361016A1 (en) 2000-10-05
RU2001126579A (ru) 2004-02-27
CZ20013449A3 (cs) 2001-12-12
CO5160290A1 (es) 2002-05-30
MXPA01009843A (es) 2002-05-06
BR0009431A (pt) 2002-01-08
IL144637A0 (en) 2002-05-23
HUP0200588A2 (hu) 2002-07-29
HK1042692A1 (zh) 2002-08-23
SK13812001A3 (sk) 2002-04-04
NZ514062A (en) 2001-09-28
PE20001587A1 (es) 2001-01-31
PL349355A1 (en) 2002-07-15
AU4290800A (en) 2000-10-16
EP1165502A1 (en) 2002-01-02
CN1345309A (zh) 2002-04-17
WO2000058279A1 (en) 2000-10-05
TR200102225T2 (tr) 2002-01-21
KR20010105394A (ko) 2001-11-28
NO20014702D0 (no) 2001-09-27
NO20014702L (no) 2001-09-27

Similar Documents

Publication Publication Date Title
JP2002540189A (ja) ジアリール誘導体およびその医薬としての使用
US5569674A (en) Heteroacetic acid derivatives
AU721452B2 (en) Antidiabetic agents
US7449599B2 (en) Phenyl carboxamide compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease
US20040248850A1 (en) Compounds for the treatment of HIV infection
JP2008515998A (ja) 化合物
JP2009517417A (ja) Ｃｒｔｈ２レセプター活性を有するオキサジアゾール誘導体類
JP2002539155A (ja) Ｌｘｒ調節剤
KR20070047319A (ko) 호흡기 질환 치료용 비페닐옥시아세트산 유도체
JP2022529615A (ja) Ｍａｓ関連ｇタンパク質受容体ｘ４のモジュレーターおよび関連製品ならびに方法
JP2005511686A (ja) 新規な化合物及びそれらの医薬における使用、それらの調製のための方法及びそれらを含有する薬学的組成物
JP2022522334A (ja) 新規な甲状腺模倣物
US6790978B2 (en) Thyromimetic organic compounds
US6599942B1 (en) Thyromimetic organic compounds
CS271469B2 (en) Method of phenoxyalkylcarboxyl acid's derivatives production
TWI712600B (zh) 作為免疫調節劑的聯苯化合物及其用途
JP2023530709A (ja) 甲状腺様作用剤
HUT56340A (en) Process for producing tetrahydronaphthalene derivatives and pharmaceutical compositions comprising such compounds
WO1999012534A1 (fr) Regulateurs des recepteurs actives par le proliferateur des peroxisomes
US5534532A (en) Aliphatic amino bis-aryl squalene synthase inhibitors
JPH03275657A (ja) ケイ皮酸アミド誘導体
US20020161053A1 (en) Biscyclopropanecarboxamide compounds and pharmaceutical use thereof
JP2002521437A (ja) マクロファージ・スカベンジャー受容体アンタゴニスト
JP2002201127A (ja) ウレア誘導体
JPH05125038A (ja) フエノキシアルカン酸誘導体及びその製法

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20040907

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20050308